[What is confirmed in the treatment of Fabry's disease?] / Was ist gesichert in der Therapie von Morbus Fabry?
Inn Med (Heidelb)
; 2024 Aug 06.
Article
in De
| MEDLINE
| ID: mdl-39105759
ABSTRACT
Fabry's disease is a rare X chromosome-linked inherited lysosomal storage disease characterized by insufficient metabolism of the substrate globotriaosylceramide (Gb3) due to reduced alpha-galactosidase A (AGAL) activity. Lysosomal Gb3 accumulation causes a multisystemic disease which, if untreated, reduces the life expectancy in females and males by around 10 and 20 years, respectively, due to progressive renal dysfunction, hypertrophic cardiomyopathy, cardiac arrhythmia and early occurrence of cerebral infarction. The diagnosis is confirmed by determining the reduced AGAL activity in leukocytes in males and molecular genetic detection of a -mutation causing the disease in females. The treatment comprises enzyme replacement therapy (ERT), agalsidase alfa, 0.2â¯mg/kg body weight (BW), agalsidase beta 1.0â¯mg/kg BW or pegunigalsidase alfa 1.0â¯mg/kg BW every 2 weeks i.v. or oral chaperone therapy (one capsule of migalastat 123â¯mg every other day) in the presence of amenable mutations. This article summarizes the data on the treatment of Fabry's disease and on complications in practice. The current guideline recommendations are addressed and new study results that could expand the therapeutic repertoire in the future are discussed.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
De
Journal:
Inn Med (Heidelb)
Year:
2024
Document type:
Article